NASDAQ:WINT - Windtree Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.13
  • Forecasted Upside: 362.33 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.19
▼ -0.01 (-0.45%)
1 month | 3 months | 12 months
Get New Windtree Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WINT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WINT

Average Price Target: $10.13
▲ +362.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Windtree Therapeutics in the last 3 months. The average price target is $10.13, with a high forecast of $12.25 and a low forecast of $8.00. The average price target represents a 362.33% upside from the last price of $2.19.

Buy

The current consensus among 2 polled investment analysts is to buy stock in Windtree Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021OppenheimerInitiated CoverageOutperform$8.00High
6/26/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.25Medium
6/30/2017Stifel NicolausDowngradeBuy ➝ HoldHigh
10/30/2016HC WainwrightSet Price TargetBuy$24.00N/A
(Data available from 6/21/2016 forward)
Windtree Therapeutics logo
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Read More

Today's Range

Now: $2.19
Low: $2.15
High: $2.31

50 Day Range

MA: $2.10
Low: $1.68
High: $2.79

52 Week Range

Now: $2.19
Low: $1.58
High: $10.06

Volume

938,000 shs

Average Volume

1,803,730 shs

Market Capitalization

$57.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Windtree Therapeutics?

The following Wall Street analysts have issued stock ratings on Windtree Therapeutics in the last year: LADENBURG THALM/SH SH, and Oppenheimer Holdings Inc..
View the latest analyst ratings for WINT.

What is the current price target for Windtree Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Windtree Therapeutics in the last year. Their average twelve-month price target is $10.13, suggesting a possible upside of 362.3%. LADENBURG THALM/SH SH has the highest price target set, predicting WINT will reach $12.25 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $8.00 for Windtree Therapeutics in the next year.
View the latest price targets for WINT.

What is the current consensus analyst rating for Windtree Therapeutics?

Windtree Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WINT will outperform the market and that investors should add to their positions of Windtree Therapeutics.
View the latest ratings for WINT.

What other companies compete with Windtree Therapeutics?

How do I contact Windtree Therapeutics' investor relations team?

Windtree Therapeutics' physical mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The company's listed phone number is 215 488 9300 and its investor relations email address is [email protected] The official website for Windtree Therapeutics is www.windtreetx.com.